All In Biotech

Free tool

FAERS Monitor: Minipress

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017442 or its brand name (Minipress, Prazosin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,387

Serious

873

63% of reports

Hospitalization

415

Death reported

91

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue115
  • off label use106
  • abdominal pain105
  • product dose omission issue104
  • drug ineffective91
  • nausea89
  • diarrhoea75
  • pain74
  • renal impairment72
  • heart failure with preserved ejection fraction69
  • headache67
  • dyspnoea63
  • hypotension62
  • dizziness60
  • haematuria60

Reports by year received

View as table
YearReports
20049
20059
20066
20084
200915
201022
201112
201221
201318
201412
201514
201616
201722
201817
201932
202047
202165
2022177
2023144
2024244
2025298
2026183

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,772 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
heart failure with preserved ejection fractionSignal694654.83572.8242,150
haematuriaSignal6026.620.81,453
renal impairmentSignal7213.010.4789
abdominal painSignal1056.85.7524
product dose omission issueSignal1045.44.5370
hypotensionSignal624.73.7178
fatigueSignal1152.21.981
off label use1061.81.541
pain741.81.528
dizziness601.81.422
diarrhoea751.81.425
nausea891.71.426
dyspnoea631.71.317
headache671.61.316
drug ineffective911.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.